quantbrah

Trading the situation. AI turns X posts into trackable portfolios. Not financial advice.

Lilly’s retatrutide data points to continued obesity-drug leadership and share gains versus current GLP-1 incumbents

The post makes a direct, forward-looking claim that Lilly’s Phase 3 retatrutide results are so strong that the drug will surpass tirzepatide and semaglutide and become the leading obesity therapy. The cleanest market translation is a concentrated long in Eli Lilly, with a smaller short in Novo Nordisk as the most exposed incumbent whose semaglutide franchise risks relative competitive pressure.

ALL TIME RETURN +6.43%
S&P 500 +1.30%
VS S&P 500 +5.13%
Return -5.81%
S&P 500 +0.60%
VS S&P 500 -6.41%
Best performer NVO +0.69%
Portfolio S&P 500 AS OF JUL 14, 7:45 PM
  • LLY Long
    Performance +10.76%
    Current weight 79.98%

    Description Retatrutide Phase 3 success strengthens Lilly’s obesity franchise and future market-share leadership.

  • NVO Short
    Performance -10.87%
    Current weight 20.02%

    Description Semaglutide franchise faces relative share and perception pressure from stronger Lilly data.

Created
Last checked
Positions
2

Not financial advice. Hypothetical portfolio for informational purposes only. Returns are approximate and do not account for splits, dividends, borrow costs, or financing. Privacy notice.